IL2 and nephrotic syndrome: Expansion of Tregs by low dose-IL2 could represent an alternative to cell therapy with Tregs infusion in patients with nephrotic syndrome refractory to all other treatments (i.e. steroids, calcineurin inhibitors, anti-CD20 monoclonal antibodies).